Close Menu

NEW YORK (360Dx) – Reimbursement cuts driven by the Protecting Access to Medicare Act, or PAMA, have raised concerns across the lab industry, but few segments stand to be more affected than the nursing home testing business.

Given their customer base, labs focused on nursing home testing have particularly high exposure to PAMA's impact. This, combined with the business's traditionally low margins and labor intensive nature, has raised questions as to how such firms will manage to stay afloat as the law's rollout continues.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.